SPY321.85+2.93 0.92%
DIA268.58+1.99 0.75%
IXIC10,555.70+67.13 0.64%
News
CELG-RT
--
0.00%
--
Bristol-Myers Placed A Big Bet On Celgene�s Pipeline. Will It Pay Off For Investors?
MotleyFool.com · 12/16/2019 14:55
Better Buy: Gilead Sciences vs. Amgen
MotleyFool.com · 12/15/2019 14:00
Here's Why You Should Own Amgen Stock in 2020
MotleyFool.com · 12/12/2019 15:38
Here�s Why bluebird bio Shares Jumped Almost 12% Today
MotleyFool.com · 12/10/2019 21:31
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
MotleyFool.com · 12/10/2019 20:54
Better Buy: Biogen vs. Amgen
MotleyFool.com · 12/08/2019 19:00
Better Buy: Pfizer vs. Bristol-Myers Squibb
MotleyFool.com · 12/08/2019 12:00
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
MotleyFool.com · 12/07/2019 13:00
2 Breast Cancer Fighting Stocks to Invest In
MotleyFool.com · 12/06/2019 14:29
$50M deal could expand NanoString Technologies diagnostic test into more markets
American City Business Journals · 12/03/2019 22:09
3 Biotech Stocks With a Lot to Prove at ASH 2019
MotleyFool.com · 12/02/2019 15:33
3 Stocks to Buy Ahead of the Next Market Crash
MotleyFool.com · 12/01/2019 12:00
Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2019 Update
Seeking Alpha - Article · 11/29/2019 15:26
Tracking John Paulson's Paulson & Company Portfolio - Q3 2019 Update
Seeking Alpha - Article · 11/29/2019 01:01
Merger Arbitrage Mondays - Novartis Confirms Acquisition Of The Medicines Company
Seeking Alpha - Article · 11/25/2019 12:13
Investing In The Holy Grail Of Cancer Treatment: Immunotherapy
Seeking Alpha - Article · 11/22/2019 18:34
The Top Large-Cap Sectors, Industries, And Stocks To Buy Now
Seeking Alpha - Article · 11/21/2019 13:00
Detailing GlaxoSmithKline's Growth Opportunities In Oncology And Upcoming BCMA Data
Seeking Alpha - Article · 11/21/2019 12:25
Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug
Nov 21- Amgen Inc on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla. Amgen now expects 2019 adjusted earnings per share between $14.50 and $14.70, up from its
Reuters · 11/21/2019 11:41
Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain
Bristol-Myers Squibb shares were indicated higher in pre-market trading after the pharmaceutical group said it has completed its $74 billion acquisition of cancer drug specialist Celgene.
The Street · 11/21/2019 10:22